Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.
Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH; Eastern Cooperative Oncology. Rowe JM, et al. Among authors: abboud cn. Blood. 2004 Jan 15;103(2):479-85. doi: 10.1182/blood-2003-05-1686. Epub 2003 Sep 25. Blood. 2004. PMID: 14512295 Free article. Clinical Trial.
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Phillips GL 2nd, Bernstein SH, Liesveld JL, Abboud CN, Becker MW, Constine LS, Ifthikharuddin JJ, Loughner JE, Milner LA, Vesole DH, Friedberg JW. Phillips GL 2nd, et al. Among authors: abboud cn. Biol Blood Marrow Transplant. 2011 Jul;17(7):1033-42. doi: 10.1016/j.bbmt.2010.11.003. Epub 2010 Nov 11. Biol Blood Marrow Transplant. 2011. PMID: 21074630 Free article. Clinical Trial.
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Walker AR, et al. Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20. Leuk Res. 2008. PMID: 18571721 Clinical Trial.
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Desai PM, et al. Among authors: abboud cn. J Clin Oncol. 2021 Oct 10;39(29):3261-3272. doi: 10.1200/JCO.20.01739. Epub 2021 Jun 22. J Clin Oncol. 2021. PMID: 34156898 Free PMC article. Clinical Trial.
Flavonoid effects on normal and leukemic cells.
Liesveld JL, Abboud CN, Lu C, McNair C, Menon A, Smith A, Rosell K, Rapoport AP. Liesveld JL, et al. Among authors: abboud cn. Leuk Res. 2003 Jun;27(6):517-27. doi: 10.1016/s0145-2126(02)00265-5. Leuk Res. 2003. PMID: 12648512
160 results